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IMPORTANCE Skin and subcutaneous diseases affect the health of millions of individuals in
the US. Data are needed that highlight the geographic trends and variations of skin disease
burden across the country to guide health care decision-making.
OBJECTIVE To characterize trends and variations in the burden of skin and subcutaneous
tissue diseases across the US from 1990 to 2017.
DESIGN, SETTING, AND PARTICIPANTS For this cohort study, data were obtained from the
Global Burden of Disease (GBD), a study with an online database that incorporates current
and previous epidemiological studies of disease burden, and from GBD 2017, which includes
more than 90 000 data sources such as systematic reviews, surveys, population-based
disease registries, hospital inpatient and outpatient data, cohort studies, and autopsy data.
The GBD separated skin conditions into 15 subcategories according to incidence, prevalence,
adequacy of data, and standardized disease definitions. GBD 2017 also estimated the burden
from melanoma of the skin and keratinocyte carcinoma. Data analysis for the present study
was conducted from September 9, 2019, to March 31, 2020.
MAIN OUTCOMES AND MEASURES Primary study outcomes included age-standardized
disability-adjusted life-years (DALYs), incidence, and prevalence. The data were stratified
by US states with the highest and lowest age-standardized DALY rate per 100 000 people,
incidence, and prevalence of each skin condition. The percentage change in DALY rates in
each state was calculated from 1990 to 2017.
RESULTS Overall, age-standardized DALY rates for skin and subcutaneous diseases increased
from 1990 (821.6; 95% uncertainty interval [UI], 570.3-1124.9) to 2017 (884.2; 95% UI,
614.0-1207.9) in all 50 states and the District of Columbia. The degree of increase varied
according to geographic location, with the largest percentage change of 0.12% (95% UI,
0.09%-0.15%) in New York and the smallest percentage change of 0.04% (95% UI,
0.02%-0.07%) in Colorado, 0.04% (95% UI, 0.01%-0.06%) in Nevada, 0.04% (95% UI,
0.02%-0.07%) in New Mexico, and 0.04% (95% UI, 0.02%-0.07%) in Utah. The
age-standardized DALY rate, incidence, and prevalence of specific skin conditions differed
among the states. New York had the highest age-standardized DALY rate for skin and
subcutaneous disease in 2017 (1097.0 [95% UI, 764.9-1496.1]), whereas Wyoming had
the lowest age-standardized DALY rate (672.9 [95% UI, 465.6-922.3]). In all 50 states and
the District of Columbia, women had higher age-standardized DALY rates for overall skin
and subcutaneous diseases than men (women: 971.20 [95% UI, 676.76-1334.59] vs men:
799.23 [95% UI, 559.62-1091.50]). However, men had higher DALY rates than women
for malignant melanoma (men: 80.82 [95% UI, 51.68-123.18] vs women: 42.74 [95% UI,
34.05-70.66]) and keratinocyte carcinomas (men: 37.56 [95% UI, 29.35-49.52] vs women:
14.42 [95% UI, 10.01-20.66]).
CONCLUSIONS AND RELEVANCE Data from the GBD suggest that the burden of skin and
subcutaneous disease was large and that DALY rate trends varied across the US; the
age-standardized DALY rate for keratinocyte carcinoma appeared greater in men. These
findings can be used by states to target interventions and meet the needs of their population.
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S kin disease is a leading cause of health burden, affect-ing millions of individuals in the US.1 The Global Bur-den of Disease (GBD) study is an effort to quantify dis-
ability and mortality statistics from hundreds of diseases and
risk factors stratified by age, sex, year, and location.2 The GBD
features both the prevalence of a health condition and its as-
sociated relative harm within a given population. The GBD is
measured by disability-adjusted life-year (DALY), which rep-
resents the sum of years of life lost (YLLs) to a disease and the
years living with disability (YLDs).2,3 One DALY is equivalent
to 1 year of healthy life lost.3 The DALY rate allows for the
consistent quantification of health burden and cross-
comparison across diverse disease states.
The GBD incorporates the most recent data and epidemio-
logical studies as they become available, making it an ideal re-
source to understand health trends over time at the global, na-
tional, and local levels.2 Tracking the incidence, prevalence,
and disability of skin and subcutaneous diseases over time is
essential for identifying modifiable risk factors that predis-
pose individuals to certain dermatological conditions. This
knowledge may represent an opportunity to aid in health care
planning, identifying root causes, improving health dispari-
ties, and even initiating action at the policy-maker level.
To identify the burden of skin and subcutaneous dis-
eases on US society, we examined the national and subna-
tional data for variations and trends in incidence, preva-
lence, and DALY rates for skin diseases in the US from 1990
to 2017.
Methods
This cohort study did not involve human subjects and used only
a data review from GBD. Therefore, institutional review board
approval was waived. GBD data review was approved by the
University of Washington. Data analysis for the present study
was conducted from September 9, 2019, to March 31, 2020.
Overview and Data Sources of GBD
For this analysis, we obtained data from the GBD, a study with
an online database that incorporates current and previous
epidemiological studies of disease burden. The data collec-
tion and estimation processes used in the GBD are explained
in this section.
Detailed descriptions of the GBD methods, including the
search and selection process, can be found in previous GBD
publications.4 Data collection and analysis followed the Guide-
lines for Accurate and Transparent Health Estimates Report-
ing (GATHER) recommendations.5,6 Fifteen skin and subcu-
taneous disease categories were selected on the basis of disease
incidence, prevalence, adequacy of data, and standardized dis-
ease definitions. These categories are as follows: acne vul-
garis; alopecia areata; atopic dermatitis; cellulitis; contact der-
matitis; decubitus ulcer; fungal skin diseases; pruritus;
psoriasis; pyoderma; scabies; seborrheic dermatitis; urti-
caria; viral skin diseases; and other skin and subcutaneous dis-
eases, which encompass miscellaneous skin conditions
(eTable 3 in the Supplement).7 In addition, GBD 20174 (which
includes more than 90 000 data sources such as systematic re-
views, surveys, population-based disease registries, hospital
inpatient and outpatient data, cohort studies, and autopsy data)
separately estimated the burden from melanoma of the skin
and keratinocyte carcinoma, which included squamous cell
carcinoma, keratoacanthoma, and basal cell carcinoma. The
cumulative category of skin and subcutaneous diseases, how-
ever, does not include malignant melanoma of the skin and ke-
ratinocyte carcinoma. Each skin disease category is defined by
International Classification of Diseases, Ninth Revision (ICD-9)
codes and International Statistical Classification of Diseases and
Related Health Problems, Tenth Revision (ICD-10) codes.4 The
GBD 2017 included additional data sources and those used in
previous GBD studies. New data for nonfatal estimations were
added from scientific literature sources, disease registries, sur-
veys, and epidemiological surveillance. New data for fatal es-
timations were added from verbal autopsy studies, cancer reg-
istries, and vital registries (record of deaths by age, sex, and
location). More than 2500 data sources were used for esti-
mates in the US. The state with the most representative data
sources was California with 412, and the state with the least
representative data sources was New Hampshire with 300. A
complete list of data sources that GBD used for estimation can
be found on the Global Health Data Exchange website.8
Estimation of Nonfatal Disease Burden
Nonfatal disease burden was estimated for each skin and sub-
cutaneous disease to include disease-specific incidence, preva-
lence, and YLDs. All raw nonfatal data were modeled with
DisMod-MR, version 2.1 (World Health Organization), a bayes-
ian meta-regression tool. In brief, GBD estimation was done
in 7 steps: (1) data compilation and extraction, (2) data adjust-
ment, (3) estimation of incidence and prevalence using
DisMod-MR 2.1 or additional modeling processes, (4) estima-
tion of severity distributions, (5) disability weights, (6) comor-
bidity adjustment, and (7) estimation of YLDs.
The YLDs were calculated by multiplying the prevalence
of each disease or sequelae by the disability weight for that
health state.9 Disability weights represent the severity of health
loss associated with a health state and are measured on a scale
from 0 (full health) to 1 (a state equivalent to death). Online
Key Points
Question Has the burden of skin and subcutaneous diseases
varied across the US from 1990 to 2017?
Findings This cohort study of patients included in the Global
Burden of Disease database from 1990 to 2017 evaluated skin
and subcutaneous disease burden across the US, the
disability-adjusted life-year rate, incidence, and prevalence of
skin disease increased from 1990 to 2017, and disease burden
varied by geographic location. The highest age-standardized
disability-adjusted life-year rate was found in New York,
whereas Wyoming had the lowest rate.
Meaning These epidemiological national data on disease burden
can guide future research efforts, allocation of resources,
prevention strategies, and targeted treatment of skin conditions.
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and international population surveys were used to identify dis-
ability weights for 234 health states, including skin and sub-
cutaneous diseases, by describing the experience of disease
in lay language.10 Health states for skin and subcutaneous dis-
eases assess physical deformity, psychosocial well-being, itch,
and pain.
Estimation of Fatal Disease Burden
The mortality burden of a disease was estimated by calculat-
ing YLLs attributable to a disease. The YLLs are the sum of each
cause-specific death multiplied by the remaining life
expectancy,3,10 and each death is attributed to a single cause.
The YLLs were calculated for the following skin conditions
only: malignant melanoma of the skin, keratinocyte carci-
noma, bacterial skin diseases, decubitus ulcers, and other skin
and subcutaneous diseases. Detailed methods are available in
the GBD 2017 causes-of-death publication and its appendices.11
Mortality data were processed in the Cause of Death En-
semble model, an analytical tool that combines a diverse set
of plausible models with predictive covariates into the highest-
quality projections for each cause-specific death. Mortality at-
tributed to malignant melanoma of the skin was estimated
through identifying and collecting available data, creating in-
dividual predictive models based on this data, and combin-
ing differently weighted predictive models to obtain the high-
est predictive validity. Additional details of this process are
provided in the supplementary appendix of the GBD 2017
publication.11
Calculation of Disability-Adjusted Life-Years
As described, YLDs and YLLs were added to yield DALY rates
are per 100 000. All estimates included uncertainty intervals
(UIs), which were calculated by running 1000 draws from
the posterior distribution of each estimate and identifying the
2.5 and 97.5 percentiles.
Statistical Analysis
All estimates were generated with 1000 draws from the
gposterior distribution of the quantity of interest. This pro-
cess produced the 95% UIs.
Results
Change in Skin and Subcutaneous Disease Burden
In the US, including the District of Columbia, the age-
standardized DALY rate per 100 000 people for skin and sub-
cutaneous diseases ranked number 12 among all other condi-
tions in 2017 compared with number 15 in 1990. The burden
from total skin and subcutaneous diseases increased from 1990
(821.6; 95% UI, 570.3-1124.9) to 2017 (884.2; 95% UI, 614.0-
1207.9), with a percentage change in age-standardized DALY
rate of 0.08% (95% UI, 0.06%-0.09%) (Table). The regional in-
crease in skin and subcutaneous disease burden varied by state,
with the largest percentage change of 0.12% (95% UI, 0.09%-
0.15%) in New York and the smallest percentage change of
0.04% (95% UI, 0.02%-0.07%) in Colorado, 0.04% (95% UI,
0.01%-0.06%) in Nevada, 0.04% (95% UI, 0.02%-0.07%) in
New Mexico, and 0.04% (95% UI, 0.02%-0.07%) in Utah. These
results are summarized in the Table.
Geographic Variation in Total and Cause-Specific Skin
and Subcutaneous Diseases
The data show geographic variation in the incidence, preva-
lence, and DALY rate for skin and subcutaneous diseases among
US states and the District of Columbia in 2017; however, the
UIs of DALY rates for skin and subcutaneous diseases over-
lapped for all states, indicating no statistical difference. Thus,
the differences discussed earlier represent potential trends and
not statistical differences. The greatest burden of skin and sub-
cutaneous diseases was concentrated along the coastal re-
gions of the US, whereas the burden from melanoma was great-
est in northern states and the burden from keratinocyte
carcinoma was highest in southern states (Figure).
The states with the highest and lowest age-standardized
DALY rate (New York [1097.0] and Wyoming [672.9]), inci-
dence (New York [44 821.8] and Wyoming [30 486.1]), and
prevalence (New York [33 360.6] and Wyoming [22 353.2])
cumulatively and individually for each of the 15 skin and
subcutaneous diseases, other skin and subcutaneous dis-
eases, malignant melanoma of the skin, and keratinocyte car-
cinoma are shown in eTable 1 in the Supplement. Cumula-
tively, the highest DALY rate, incidence, and prevalence were
found in New York, and the lowest rates were found in
Wyoming. The greatest DALY rate for melanoma was found in
Kentucky (76.6), whereas the greatest prevalence (189.8) and
incidence (22.7) of melanoma were found in Massachusetts.
For keratinocyte carcinoma (basal cell carcinoma and squa-
mous cell carcinoma), the highest DALY rate (0.3), preva-
lence (83.1), and incidence (943.9) were found in Florida.
The 10 most prevalent skin diseases in the US in 2017, ex-
cluding keratinocyte carcinoma and malignant melanoma, are
listed in eTable 4 in the Supplement. The District of Columbia
had a higher prevalence of atopic dermatitis (6332.1), sebor-
rheic dermatitis (714.3), and alopecia areata (504.9). New York
had the highest prevalence of acne vulgaris (5568.1), fungal
skin diseases (3585.8), and psoriasis (3516.4). Louisiana had
a higher prevalence of cellulitis (152.0).
Sex Differences in Cause-Specific Skin
and Subcutaneous Diseases in 2017
The age-standardized DALY rates for total skin and subcuta-
neous diseases, malignant melanoma, and keratinocyte car-
cinoma were compared in men vs women in 2017 (eTable 2 in
the Supplement). For each state, no significant difference was
found in DALY rates in men and women for age-standardized
skin and subcutaneous diseases (men: 799.23 [95% UI, 559.62-
1091.50] vs women: 971.20 [95% UI, 676.76-1334.59]). Simi-
larly, for all states, no significant difference was found be-
tween men and women for age-standardized malignant
melanoma DALY rates (men: 80.82 [95% UI, 51.68-123.18]
vs women: 42.74 [95% UI, 34.05-70.66]). In contrast, each
state showed a significant difference between men and
women for age-standardized keratinocyte carcinoma DALY
rate (men: 37.56 [95% UI, 29.35-49.52] vs women: 14.42
[95% UI, 10.01-20.66]). Florida had the largest difference in
Burden of Skin and Subcutaneous Diseases in the US From 1990 to 2017 Original Investigation Research
jamadermatology.com (Reprinted) JAMA Dermatology Published online June 10, 2020 E3
© 2020 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of Edinburgh Library User  on 06/15/2020
Table. Total Rate and Percentage Change of Disability-Adjusted Life-years (DALYs) by US State, 1990-2017a
State
Age-standardized DALYs, (95% UI)
Rate per 100 000 Percentage change
1990 2017 1990-2017
All states plus DC 821.6 (570.3-1124.9) 884.2 (614.0-1207.9) 0.08 (0.06-0.09)
Alabama 745.6 (518.0-1022.5) 796.5 (551.8-1094.4) 0.07 (0.04-0.09)
Alaska 691.7 (481.2-947.1) 735.4 (516.2-1005.2) 0.06 (0.04-0.09)
Arizona 814.2 (554.3-1122.8) 856.9 (593.7-1178.4) 0.05 (0.03-0.08)
Arkansas 675.9 (472.1-926.2) 724.0 (506.9-990.3) 0.07 (0.05-0.10)
California 856.9 (581.4-1178.0) 911.9 (629.9-1245.4) 0.06 (0.04-0.09)
Colorado 733.1 (505.1-1007.9) 765.6 (533.6-1050.8) 0.04 (0.02-0.07)
Connecticut 931.3 (646.8-1274.0) 1009.3 (703.9-1375.4) 0.08 (0.06-0.11)
Delaware 801.2 (557.2-1099.1) 859.4 (599.9-1174.0) 0.07 (0.05-0.10)
District of Columbia 991.8 (685.4-1371.7) 1052.8 (728.6-1450.4) 0.06 (0.04-0.09)
Florida 847.7 (587.1-1167.5) 924.3 (643.7-1268.0) 0.09 (0.07-0.12)
Georgia 831.5 (576.3-1143.4) 909.4 (629.3-1248.6) 0.09 (0.07-0.12)
Hawaii 915.6 (631.7-1264.3) 977.7 (677.4-1338.4) 0.07 (0.05-0.09)
Idaho 723.1 (502.3-990.1) 760.8 (528.1-1042.3) 0.05 (0.03-0.08)
Illinois 765.2 (533.6-1048.3) 829.3 (578.7-1134.0) 0.08 (0.06-0.11)
Indiana 758.0 (522.2-1037.0) 808.2 (562.6-1105.9) 0.07 (0.04-0.10)
Iowa 718.1 (499.1-987.2) 763.4 (531.3-1041.8) 0.06 (0.04-0.09)
Kansas 721.7 (498.4-987.2) 772.0 (538.2-1053.1) 0.07 (0.05-0.10)
Kentucky 787.3 (544.3-1077.4) 854.8 (597.8-1177.5) 0.09 (0.06-0.11)
Louisiana 848.8 (593.5-1168.3) 924.8 (645.3-1271.2) 0.09 (0.07-0.12)
Maine 720.7 (508.4-982.1) 774.6 (541.6-1049.0) 0.07 (0.05-0.10)
Maryland 866.0 (597.2-1185.1) 940.0 (648.8-1284.4) 0.09 (0.06-0.11)
Massachusetts 890.7 (620.6-1222.3) 967.4 (676.7-1317.9) 0.09 (0.06-0.11)
Michigan 839.8 (581.6-1153.8) 893.5 (622.9-1226.8) 0.06 (0.04-0.09)
Minnesota 731.9 (509.4-1006.1) 787.0 (549.9-1073.5) 0.08 (0.05-0.10)
Mississippi 663.9 (461.6-905.6) 708.9 (496.7-971.1) 0.07 (0.04-0.10)
Missouri 733.1 (508.3-1002.1) 781.9 (549.9-1074.2) 0.07 (0.04-0.09)
Montana 696.3 (484.3-953.4) 731.8 (514.5-1004.8) 0.05 (0.03-0.08)
Nebraska 714.4 (493.2-978.7) 757.8 (529.4-1036.0) 0.06 (0.04-0.08)
Nevada 744.4 (510.5-1023.4) 772.3 (534.9-1056.5) 0.04 (0.01-0.06)
New Hampshire 766.8 (536.2-1047.7) 825.2 (582.8-1122.5) 0.08 (0.05-0.10)
New Jersey 924.1 (641.1-1271.4) 1014.9 (703.1-1396.3) 0.10 (0.08-0.13)
New Mexico 696.7 (478.4-957.4) 725.3 (499.9-999.7) 0.04 (0.02-0.07)
New York 983.3 (675.0-1349.9) 1097.0 (764.9-1496.1) 0.12 (0.09-0.15)
North Carolina 782.2 (542.6-1070.8) 844.2 (591.6-1157.0) 0.08 (0.06-0.11)
North Dakota 673.7 (469.4-924.9) 719.1 (501.3-979.4) 0.07 (0.04-0.09)
Ohio 805.9 (556.9-1111.1) 860.4 (600.5-1173.3) 0.07 (0.04-0.10)
Oklahoma 756.8 (525.3-1036.5) 805.5 (558.9-1104.0) 0.06 (0.04-0.09)
Oregon 836.2 (575.8-1147.0) 907.9 (629.0-1243.9) 0.09 (0.06-0.11)
Pennsylvania 817.6 (570.5-1119.2) 898.7 (626.1-1226.7) 0.10 (0.07-0.13)
Rhode Island 834.5 (578.9-1146.8) 894.8 (629.2-1228.8) 0.07 (0.05-0.10)
South Carolina 844.5 (590.0-1158.6) 920.3 (642.3-1264.6) 0.09 (0.07-0.12)
South Dakota 704.5 (487.4-969.4) 751.1 (526.5-1030.5) 0.07 (0.04-0.09)
Tennessee 757.1 (525.5-1037.8) 807.8 (560.5-1109.5) 0.07 (0.04-0.10)
Texas 819.4 (564.4-1126.7) 888.3 (617.6-1215.5) 0.08 (0.06-0.11)
Utah 722.8 (495.9-1003.8) 754.2 (521.8-1046.8) 0.04 (0.02-0.07)
Vermont 702.3 (492.1-963.1) 744.7 (521.9-1014.9) 0.06 (0.04-0.09)
(continued)
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age-standardized DALY rate for keratinocyte carcinoma be-
tween men (52.73; 95% UI, 38.36-75.45) and women (21.04;
95% UI, 13.19-32.82), whereas North Dakota had the smallest
difference between men (25.23; 95% UI, 20.06-32.78) and
women (10.95; 95% UI, 7.88- 15.28).
Discussion
This cohort study reported on the skin and subcutaneous dis-
ease burden in the US and the marked variations at the state
level. The overall skin and subcutaneous disease burden across
the US slightly increased from 1990 (821.6) to 2017 (884.2)
(Table). The reported variation in DALY rates at state levels may
point out factors that are unique to each state and may be as-
sociated with the disparities in DALY rates. Many reasons may
explain the DALY rate variation, including socioeconomic sta-
tus, access to and quality of dermatological care, insurance cov-
erage, public health screening and prevention programs, demo-
graphic characteristics (eg, age, sex, educational level, income
level, and occupation), migration patterns, weather and
climate, environmental exposures, types of dermatology
practice, and billing patterns of individual states. Moreover,
data reporting and consistency, adequate ICD-9 or ICD-10
codes, and the health care database used may also alter the
DALY rates in states.
In contrast, a study that evaluated cardiovascular dis-
eases across the US reported a decrease in DALY rates from 1990
to 2016 in all states,12 thereby raising the possibility that other
dermatological factors may be associated with the burden of
skin and subcutaneous diseases across the US. Such derma-
tological factors may include greater screening for skin con-
ditions, increase in disease prevalence, and geographic distri-
bution of dermatologists over time.
The highest DALY rate for skin and subcutaneous disease
burden was observed in New York, whereas Wyoming had the
lowest value, yet no significant differences between the states
were found. Florida had the greatest burden from keratino-
cyte carcinoma, which is concordant with Florida’s moderate
to very high UV index and the known key role of UV radiation
in keratinocyte carcinomas.13 Not surprisingly, the lowest DALY
rate of keratinocyte carcinoma was observed in Alaska. This
information may be used to guide health care allocation, op-
timize skin cancer screening, and promote preventive efforts
to reduce keratinocyte carcinoma burden in higher-risk states.
Many factors may explain the difference in prevalence in
skin diseases, including local weather, climate change, diet,
characteristics of the state population, and data reporting. The
states with the highest prevalence also had the highest inci-
dence of each respective disease. Interestingly, Kentucky had
the highest age-standardized DALY rate for malignant mela-
noma of the skin despite the higher disease prevalence and in-
cidence being reported in the state of Massachusetts. As both
states have similar race/ethnicity demographics, with white
individuals composing more than 80% of the population,14
health care–based factors, including dermatologist density and
health insurance coverage, might be associated with the higher
observed DALY rate.15
Although no significant sex difference was observed for
the age-standardized DALY rates for skin and subcutaneous
diseases and malignant melanoma, men had the highest rate
for keratinocyte carcinoma. Previous studies have eluci-
dated sex differences, revealing men to be more susceptible
to infectious skin disease and melanoma and women to be
more susceptible to pigmentary disorders, autoimmune dis-
eases, and allergic skin diseases.16 Sex-based differences may
be affected by skin structure and function, sex hormones,
immune responses, work exposures, and sociocultural
backgrounds.16 The higher observed age-standardized DALY
rate for keratinocyte carcinomas in men may be associated with
poor sun-protective behaviors (eg, sunscreen application, wear-
ing wide brim hats, limiting outdoor activity, and seeking
shade), outdoor work, delayed screening and diagnosis, and
less worry about recurrence.17-20
We believe that the diversity of state-level burden is de-
pendent on a collection of factors, including socioeconomic
status, demographic characteristics, environmental expo-
sures, climate and weather patterns, access to and quality of
dermatological care, dermatology practice types available, and
local health care policy and budget. Furthermore, the burden
of skin disease across the US may reflect the development
of new treatments, access to health care, and an aging US
population.21 Stratifying individual state burden according
to the GBD data may help with allocation of health resources,
Table. Total Rate and Percentage Change of Disability-Adjusted Life-years (DALYs) by US State, 1990-2017a (continued)
State
Age-standardized DALYs, (95% UI)
Rate per 100 000 Percentage change
1990 2017 1990-2017
Virginia 837.2 (573.7-1150.0) 906.9 (626.9-1241.9) 0.08 (0.06-0.11)
Washington 836.9 (577.0-1141.3) 905.0 (631.8-1232.3) 0.08 (0.06-0.11)
West Virginia 757.6 (526.4-1034.8) 820.2 (573.2-1119.2) 0.08 (0.06-0.11)
Wisconsin 735.7 (510.6-1007.5) 783.3 (547.7-1070.6) 0.06 (0.04-0.09)
Wyoming 641.9 (442.5-879.1) 672.9 (465.6-922.3) 0.05 (0.02-0.08)
Abbreviations: DC, District of Columbia; UI, uncertainty interval.
a The categories of skin and subcutaneous disease conditions selected for
monitoring by the Global Burden of Disease study were dermatitis (atopic,
seborrheic, and contact), psoriasis, cellulitis, pyoderma, scabies, fungal skin
diseases, viral skin diseases, acne vulgaris, alopecia areata, pruritus, urticaria,
decubitus ulcer, and other skin and subcutaneous diseases. Malignant
melanoma of the skin and keratinocyte carcinoma were not included.
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Figure. Maps of Age-Standardized Disability-Adjusted Life-Year (DALY) Rate for Total Skin and Subcutaneous Conditions in 1990 and 2017.
A 1990 Age-standardized skin and subcutaneous diseases in the US
DALY rate per 100 000
11001000900800700600
C 1990 Age-standardized malignant melanoma of the skin in the US
DALY rate per 100 000
70605040
E 1990 Age-standardized keratinocyte carcinoma in the US
DALY rate per 100 000
40302010
B 2017 Age-standardized skin and subcutaneous diseases in the US
DALY rate per 100 000
1000900800700
D 2017 Age-standardized malignant melanoma of the skin in the US
DALY rate per 100 000
706050
F 2017 Age-standardized keratinocyte carcinoma in the US
DALY rate per 100 000
35302520
The conditions selected for monitoring by the Global Burden of Disease study
were skin and subcutaneous diseases (A and B): dermatitis (atopic, seborrheic,
and contact), psoriasis, cellulitis, pyoderma, scabies, fungal skin diseases, viral
skin diseases, acne vulgaris, alopecia areata, pruritus, urticaria, decubitus ulcer,
and other skin and subcutaneous diseases. Malignant melanoma of the skin
(C and D) and keratinocyte carcinoma (E and F) were not included in the
conditions selected for monitoring by the Global Burden of Disease study.4
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prioritization of prevention strategies, development of pub-
lic health policy, expansion of health care coverage to skin dis-
ease treatment, and guidance of future research efforts. Given
the comorbidities associated with skin diseases, these find-
ings can be used by primary care physicians and other medi-
cal specialties to meet patient needs, provide education, and
develop communication strategies to reduce stigma and so-
cial disability associated with skin diseases. Future studies
should investigate state-specific differences across the 15 dis-
ease categories (with analysis stratified by age and race/
ethnicity), direct vs indirect costs of skin diseases, and the fac-
tors that may be associated with these variations, including
sociodemographic index, insurance coverage, and dermatolo-
gist density.
Limitations
This study has several limitations. First, the GBD provides es-
timates only for 15 of the most common skin and subcutane-
ous disease categories. Less common skin conditions, such as
bullous and connective tissue disorders, were grouped under
the category of other skin and subcutaneous disease. Sec-
ond, inconsistency and underreporting may occur in various
US states, leading to possibly flawed burden-of-disease esti-
mates, such as underreporting because of improper ICD-9 or
ICD-10 coding or grouping of heterogeneous skin disease as well
as selection bias from detecting disease in persons who have
more propensity to seek health care. Inconsistencies in the data
may also stem from changes in sources over time. Third, DALY
rate measures the overall disease burden and may not ac-
count for social disability and stigma associated with skin dis-
ease. In addition, the reported GBD data lacked information
on race/ethnicity for each geographic area, which might affect
the prevalence and incidence of certain skin and subcutane-
ous diseases.
Conclusions
The burden of skin and subcutaneous diseases appeared to
be large, and the DALY rate per 100 000 people appeared
to vary across the US. The age-standardized DALY rate for
keratinocyte carcinoma was found to be higher in men than
in women. We believe that data from the GBD study can be
used to improve the ability of states to meet the health
needs of their population. The results of this cohort study
and future research may inform states’ recommendations
and targeted interventions for skin and subcutaneous dis-
ease in their populations.
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